Literature DB >> 1356442

v-erb A, nuclear hormone receptors, and oncogenesis.

M L Privalsky1.   

Abstract

Mesh：

Substances：

Year:  1992        PMID： 1356442     DOI： 10.1016/0304-419x(92)90006-k

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN： 0006-3002


× No keyword cloud information.
  8 in total

1.  Multiple mutations contribute to repression by the v-Erb A oncoprotein.

Authors:  Sangho Lee; Martin L Privalsky
Journal:  Oncogene       Date:  2005-10-13       Impact factor: 9.867

2.  The transcriptional integrator CREB-binding protein mediates positive cross talk between nuclear hormone receptors and the hematopoietic bZip protein p45/NF-E2.

Authors:  X Cheng; M J Reginato; N C Andrews; M A Lazar
Journal:  Mol Cell Biol       Date:  1997-03       Impact factor: 4.272

3.  Mutant thyroid hormone receptors (TRs) isolated from distinct cancer types display distinct target gene specificities: a unique regulatory repertoire associated with two renal clear cell carcinomas.

Authors:  Meghan D Rosen; Ivan H Chan; Martin L Privalsky
Journal:  Mol Endocrinol       Date:  2011-05-26

4.  Oncogenic transformation induced by the Qin protein is correlated with transcriptional repression.

Authors:  J Li; H Thurm; H W Chang; J S Iacovoni; P K Vogt
Journal:  Proc Natl Acad Sci U S A       Date:  1997-09-30       Impact factor: 11.205

5.  The erbA oncogene represses the actions of both retinoid X and retinoid A receptors but does so by distinct mechanisms.

Authors:  H W Chen; M L Privalsky
Journal:  Mol Cell Biol       Date:  1993-10       Impact factor: 4.272

6.  Retinoic acid receptor alpha suppresses transformation by v-myb.

Authors:  J Smarda; J Sugarman; C Glass; J Lipsick
Journal:  Mol Cell Biol       Date:  1995-05       Impact factor: 4.272

7.  Thyroid hormone receptor mutations in cancer and resistance to thyroid hormone: perspective and prognosis.

Authors:  Meghan D Rosen; Martin L Privalsky
Journal:  J Thyroid Res       Date:  2011-06-08

8.  Thyroid hormone receptor mutants implicated in human hepatocellular carcinoma display an altered target gene repertoire.

Authors:  I H Chan; M L Privalsky
Journal:  Oncogene       Date:  2009-09-14       Impact factor: 9.867
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.